Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

NCT05752552

Status	RECRUITING
Phase	Phase 1
Sponsor	DeuterOncology
Enrollment	55 participants

Key Eligibility Criteria

Inclusion (9)

- years or older
- histologically or cytologically confirmed locally advanced, unresectable or metastatic NSCLC, no longer eligible for approved, available standard therapies. To be entered patients must have proven MET exon 14 skipping mutation, determined by local next generation sequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, from an assessment not older than 3 months
- measurable disease in accordance with RECIST 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status d 1
- adequate bone marrow function, without the support of cytokines

... and 4 more (see full listing online)

Exclusion (17)

- tumour harbouring other known oncogenic mutations promoting tumour growth
- major surgery within 3 weeks before enrolment
- chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy, or any other study drug within 3 weeks before study drug administration
- antibody based cancer therapy within 4 weeks before administration of the first dose of DO-2
- patients who became progressive on previous treatment with a MET-kinase inhibitor

... and 12 more (see full listing online)

Locations (13 total)

Institut Roi Albert II - UC Louvain, Brussels, Belgium
UZA, Edegem, Belgium
Universitair Ziekenhuis Gent, Ghent, Belgium
... and 10 more locations